ENTX

3.3050.76%
HT

Haya Taitel

Non-Employee Independent Director

Ms. Haya Taitel, R.Ph, MS, serves as Non-Employee Independent Director of Entera Bio Ltd. since June 2023. She served as Senior Vice President and Chief Commercial Officer of Kadmon Holdings, Inc. since 2018. She was responsible for the strategy, tactical execution and forecasting of in-line promoted products and the launch readiness of all pipeline assets. Ms. Taitel lead commercial operation disciplines including marketing, sales, national accounts and contracting strategies. Ms. Taitel also oversaw the commercial operation infrastructure, including the business analytics, market segmentation and customer service units. Prior to joining Kadmon in early 2014, Ms. Taitel led the U.S. commercial franchises of the Pharma and Device sectors of Johnson & Johnson (J&J). In her long tenure with J&J, Ms. Taitel launched new chemical entities in several therapeutic areas including neurology, analgesia, peripheral diabetic neuropathy, women’s health and urology, with a focus on interstitial cystitis. Ms. Taitel earned her M.S. in pharmacology and Teratology from Temple University School of Pharmacy in Philadelphia, PA. Ms. Taitel earned her B.S. in Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel. She currently serves as the Head of Sanofi’s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock®, from 2013 until the company was acquired by Sanofi for 1.9 billion in November 2021.

Positions